Cargando…

COVID-19 vaccine induced interstitial lung disease

A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshifuji, Ayumi, Ishioka, Kota, Masuzawa, Yuya, Suda, Shuntaro, Murata, Saori, Uwamino, Yoshifumi, Fujino, Motoko, Miyahara, Hiromi, Hasegawa, Naoki, Ryuzaki, Munekazu, Hoshino, Haruhiko, Sekine, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450284/
https://www.ncbi.nlm.nih.gov/pubmed/34580010
http://dx.doi.org/10.1016/j.jiac.2021.09.010
_version_ 1784569607290355712
author Yoshifuji, Ayumi
Ishioka, Kota
Masuzawa, Yuya
Suda, Shuntaro
Murata, Saori
Uwamino, Yoshifumi
Fujino, Motoko
Miyahara, Hiromi
Hasegawa, Naoki
Ryuzaki, Munekazu
Hoshino, Haruhiko
Sekine, Kazuhiko
author_facet Yoshifuji, Ayumi
Ishioka, Kota
Masuzawa, Yuya
Suda, Shuntaro
Murata, Saori
Uwamino, Yoshifumi
Fujino, Motoko
Miyahara, Hiromi
Hasegawa, Naoki
Ryuzaki, Munekazu
Hoshino, Haruhiko
Sekine, Kazuhiko
author_sort Yoshifuji, Ayumi
collection PubMed
description A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio. These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes.
format Online
Article
Text
id pubmed-8450284
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-84502842021-09-20 COVID-19 vaccine induced interstitial lung disease Yoshifuji, Ayumi Ishioka, Kota Masuzawa, Yuya Suda, Shuntaro Murata, Saori Uwamino, Yoshifumi Fujino, Motoko Miyahara, Hiromi Hasegawa, Naoki Ryuzaki, Munekazu Hoshino, Haruhiko Sekine, Kazuhiko J Infect Chemother Case Report A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio. These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes. Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022-01 2021-09-20 /pmc/articles/PMC8450284/ /pubmed/34580010 http://dx.doi.org/10.1016/j.jiac.2021.09.010 Text en © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Case Report
Yoshifuji, Ayumi
Ishioka, Kota
Masuzawa, Yuya
Suda, Shuntaro
Murata, Saori
Uwamino, Yoshifumi
Fujino, Motoko
Miyahara, Hiromi
Hasegawa, Naoki
Ryuzaki, Munekazu
Hoshino, Haruhiko
Sekine, Kazuhiko
COVID-19 vaccine induced interstitial lung disease
title COVID-19 vaccine induced interstitial lung disease
title_full COVID-19 vaccine induced interstitial lung disease
title_fullStr COVID-19 vaccine induced interstitial lung disease
title_full_unstemmed COVID-19 vaccine induced interstitial lung disease
title_short COVID-19 vaccine induced interstitial lung disease
title_sort covid-19 vaccine induced interstitial lung disease
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450284/
https://www.ncbi.nlm.nih.gov/pubmed/34580010
http://dx.doi.org/10.1016/j.jiac.2021.09.010
work_keys_str_mv AT yoshifujiayumi covid19vaccineinducedinterstitiallungdisease
AT ishiokakota covid19vaccineinducedinterstitiallungdisease
AT masuzawayuya covid19vaccineinducedinterstitiallungdisease
AT sudashuntaro covid19vaccineinducedinterstitiallungdisease
AT muratasaori covid19vaccineinducedinterstitiallungdisease
AT uwaminoyoshifumi covid19vaccineinducedinterstitiallungdisease
AT fujinomotoko covid19vaccineinducedinterstitiallungdisease
AT miyaharahiromi covid19vaccineinducedinterstitiallungdisease
AT hasegawanaoki covid19vaccineinducedinterstitiallungdisease
AT ryuzakimunekazu covid19vaccineinducedinterstitiallungdisease
AT hoshinoharuhiko covid19vaccineinducedinterstitiallungdisease
AT sekinekazuhiko covid19vaccineinducedinterstitiallungdisease